Valuation: Acrux Limited

Market Cap 6.67M 4.59M 4.02M 3.71M 3.47M 6.52M 434M 44.66M 17.24M 214M 17.24M 16.86M 743M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 9.44M 6.5M 5.69M 5.25M 4.91M 9.23M 614M 63.21M 24.4M 303M 24.4M 23.87M 1.05B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day-7.69%
1 week-7.69%
3 months+9.09%
6 months-20.00%
Current year-20.00%
1 week 0.01
Extreme 0.012
0.01
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-7.69%-7.69%-25.00%-71.43% 4.59M
-0.66%-0.29%+11.15%+77.11% 47.58B
-0.96%+0.89%+51.10%+104.99% 35.47B
+0.78%+2.25%-2.69%+44.38% 12.42B
-0.78%+0.04%+12.39%+90.82% 11.83B
+2.46%-2.31%+32.29%+118.03% 8.79B
+1.41%+2.60%+22.40%+45.37% 7.09B
-0.91%+2.53%+53.18%-8.37% 6.99B
+0.81%+1.14%+25.69%+226.08% 6.53B
+9.12%+6.89%-29.64%+6.47% 5.4B
Average +0.36%+1.04%+15.09%+63.35% 14.21B
Weighted average by Cap. +0.10%+1.73%+23.07%+83.25%

Financials

2024 2025
Net sales 5.09M 3.5M 3.07M 2.83M 2.64M 4.98M 331M 34.08M 13.15M 163M 13.16M 12.87M 567M 1.19M 819K 717K 662K 618K 1.16M 77.42M 7.96M 3.07M 38.19M 3.08M 3.01M 133M
Net income -5.8M -3.99M -3.49M -3.23M -3.01M -5.67M -377M -38.82M -14.99M -186M -14.99M -14.66M -646M -5.94M -4.09M -3.58M -3.31M -3.09M -5.81M -387M -39.79M -15.36M -191M -15.36M -15.03M -662M
Net Debt 759K 522K 457K 422K 394K 742K 49.38M 5.08M 1.96M 24.36M 1.96M 1.92M 84.57M 2.77M 1.91M 1.67M 1.54M 1.44M 2.71M 180M 18.55M 7.16M 88.96M 7.16M 7.01M 309M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
30/06/26 $0.0120 -7.69% 622,468
29/06/26 $0.0130 -7.14% 237,052
26/06/26 $0.0140 +7.69% 789,030
25/06/26 $0.0130 -7.14% 1,327,517
24/06/26 $0.0140 +7.69% 369,855

Annual profits - Rate of surprise